



This is a repository copy of *Bracken fern carcinogen, Ptaquiloside, forms a guanine O6-adduct in DNA.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/221999/>

Version: Published Version

Article:

Keskin, F., Noone, H., Dickman, M.J. orcid.org/0000-0002-9236-0788 et al. (8 more authors) (2025) Bracken fern carcinogen, Ptaquiloside, forms a guanine O6- adduct in DNA. *Journal of Agricultural and Food Chemistry*, 73 (2). pp. 1053-1061. ISSN 0021-8561

<https://doi.org/10.1021/acs.jafc.4c07187>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Bracken Fern Carcinogen, Ptaquiloside, Forms a Guanine O⁶-Adduct in DNA

Fourat Keskin, Hannah Noone, Mark J. Dickman, Esther Allen, William D. Mulcrone, Lars Holm Rasmussen, Hans Christian Bruun Hansen, Peter J. O'Connor, Andrew C. Povey, Geoffrey P. Margison, and David M. Williams*



Cite This: *J. Agric. Food Chem.* 2025, 73, 1053–1061



Read Online

ACCESS |



Metrics & More



Article Recommendations



Supporting Information

ABSTRACT: Bracken fern (*Pteridium* sp.) is a viable and vigorous plant with invasive potential, ingestion of which causes chronic illness and cancers in farm animals. Bracken is a suspected human carcinogen, and exposure can result from ingestion of bracken-contaminated water, dairy products, or meat derived from livestock grazing on bracken fern. Bracken is also consumed in the diets of some communities. Ptaquiloside (PTQ), a known bracken carcinogen, is an illudane-type glycoside that forms a highly reactive electrophile, PTQ dienone, known to produce *N*⁷-guanine and *N*³-adenine adducts in DNA. Here, we demonstrate for the first time that PTQ dienone also produces an *O*⁶-alkylguanine (*O*⁶-PTBguanine) in DNA. Since *O*⁶-alkylguanines in DNA can be mutagenic, this work provides a potential mechanistic link between PTQ exposure and carcinogenicity. *O*⁶-PTBguanine is poorly repaired by *O*⁶-methylguanine-DNA methyltransferase that acts on other *O*⁶-alkylguanines, further highlighting the potential risk of exposure to bracken and PTQ.


KEYWORDS: bracken fern, ptaquiloside, carcinogenicity, *O*⁶-alkylguanine, MGMT

INTRODUCTION

Bracken fern (*Pteridium* sp.) or bracken is an aggressively growing plant found extensively throughout temperate and subtropical areas of the World. The most common species, *Pteridium aquilinum*, is widespread in Europe and covers approximately 1.6% of the UK land mass.¹ Bracken fern is typically found near woodland, along forest tracks, and on the forest floor below canopy openings. In upland areas, bracken often dominates moors and heathland. Bracken poisoning in farm animals is well-documented² and characterized by a variety of different ailments. These include thiamine deficiency and a depression of bone marrow activity, leading to severe leukopenia and acute hemorrhaging. Chronic bracken poisoning causes progressive retinal degeneration in sheep and is associated with tumors of the upper alimentary tract and bladder in cattle.²

The toxicity and carcinogenicity associated with bracken have been known for over 50 years.³ The first “active” carcinogen contained in bracken was identified in 1983 as ptaquiloside (PTQ, Scheme 1), an illudane-type glycoside.⁴ PTQ and PTQ-dienone are carcinogenic, but there are no reports of a dose response curve in rats and mice. However, intragastric administration of PTQ to rats has been shown to induce mammary cancer (100%) and ileal tumors (91%) in dose levels of 300 and 380 mg, respectively.⁵ Following the discovery of PTQ, structurally similar illudane glycosides have been found in bracken, of which caudatoside and ptesculentoside are the most well-studied.⁶ Potential routes of human exposure to PTQ and other illudane glycosides include contaminated surface water, soil, and groundwater in bracken-infested areas.² Field studies demonstrate substantial PTQ wash-off from bracken during rain events, resulting in elevated PTQ concentrations in pore water,

Scheme 1. Decomposition of Ptaquiloside to Ptaquilosin, Pterosin B, and PTQ Dienone That Can Cause DNA Damage




eventually resulting in contamination of surface and groundwater, including drinking water reservoirs. Exposure through dietary routes include the milk of grazing cattle and the meat of calves fed on a diet containing bracken.⁷ In several parts of the world, bracken is consumed by humans, particularly bracken crosiers harvested in spring.⁸ Exposure may also take place via inhalation of spores⁹ and by skin exposure to bracken leaves, but the risk is hardly quantified. However, although bracken is designated by the WHO/IARC as a possibly carcinogenic to humans,¹⁰ detailed studies supporting this or indeed the consequences of human exposure to PTQ are not available.

Received: August 8, 2024

Revised: December 11, 2024

Accepted: December 12, 2024

Published: January 7, 2025






Figure 1. Structures of alkylated adenine and guanine formed following the reaction of DNA or guanosine with PTQ dienone: 1 and 2 have been identified in reactions with DNA²⁰ following thermal hydrolysis/depurination and 2 and 3 have been identified in the reaction of PTQ dienone with guanosine.¹²

PTQ seems to be the most abundant illudane glycoside¹¹ and is highly soluble in water and relatively stable at neutral or slightly acidic pH. However, below pH 4, PTQ has a half-life of just a few hours, undergoing elimination of glucose and formation of ptaquilosin (Scheme 1). Hydrolysis of ptaquilosin produces pterisin B (PTB).^{12–14} At alkaline pH, PTQ decomposition occurs in minutes, forming PTQ dienone^{12–14} (Scheme 1). PTQ dienone contains a highly electrophilic spirocyclopropane moiety adjacent to a hydroxyl group. It reacts rapidly with a variety of nucleophiles including DNA bases, undergoing aromatization in the process.^{12,15} The reported mutagenicity of PTQ at slightly alkaline pH has been attributed to its conversion to PTQ dienone,¹⁶ whose carcinogenicity has also been established.¹⁷

The reactivity of PTQ dienone with selected amino acids, ribonucleosides, and the ribonucleotides AMP and GMP has been described by Yamada and co-workers.¹² Alkylation of the heterocyclic bases of the ribonucleosides resulted in products derived from the reaction of uridine (N3 and O4 atoms), cytidine (N3 atom), guanosine (N7 and O6), and adenosine (N6). However, in the latter instance, this most probably results from N1-alkylation of the adenine ring followed by a Dimroth rearrangement.¹⁸ Interestingly, no products derived from the alkylation of adenosine on the N3 position were observed. In DNA, many of these nucleophilic sites are less accessible due to the double-helical structure. Thus, in DNA duplexes, alkylation of cytosine or the N6 amino group of adenine is generally not observed.¹⁹ Subsequent studies from the Yamada group demonstrated the cleavage of double-stranded plasmid DNA following treatment with PTQ dienone (but not PTQ) and subsequent heating. Hydrolysis of the DNA was attributed to alkylation at adenine and guanine sites, followed by depurination and chain cleavage at the resulting abasic sites.^{15,20} Following treatment of salmon sperm DNA¹⁵ with PTQ dienone and subsequent heating, the alkylated *N*³-alkyladenine (*N*³-alkA) and *N*⁷-alkylguanine (*N*⁷-alkG) adducts 1 and 2 (Figure 1), respectively, were identified, with the latter being formed in a 3-fold excess. When the short oligodeoxyribonucleotide d-(ACGT)²⁰ was treated with PTQ dienone, the major product obtained was PTB, together with unreacted d-(ACGT) and a number of other DNA-derived products. The two most abundant products were isolated by HPLC and further characterized. Thus, heating these samples resulted in depurination of the alkylated purine-containing nucleosides, releasing *N*⁷-alkG and *N*³-alkA in a ratio of 2.4:1. Although *N*⁷-alkG is the major product in this reaction, it should also be noted

that hydrolysis of *N*⁷-alkGs in DNA can lead to the formation of imidazole ring-opened products through attack of water at C8.²¹ These are much more stable toward hydrolysis at the glycosidic linkage than *N*⁷-alkyl-2'-deoxyguanosines, so this may have led to an underestimation of the initial amount of this adduct. Furthermore, these studies would not identify other expected adducts such as *O*⁶-alkylguanines since these are not labile under the experimental conditions used for glycosidic bond hydrolysis.

*N*⁷-AlkGs in DNA are neither toxic nor mutagenic per se, while *N*³-alkAs can be toxic via blocking DNA replication.²² The half-lives for depurination of *N*³-alkA and *N*⁷-alkG (methyl and ethyl adducts) from DNA are approximately 6.5 and 155 h, respectively,²³ and the abasic sites generated can be mutagenic.²⁴ In contrast, *O*⁶-alkGs in DNA are significantly more stable: comparative studies of nucleoside stabilities show no decomposition of *O*⁶-MedG over 11 days, conditions under which over 80% depurination of *N*⁷-MedG occurs.²⁵ Furthermore, *O*⁶-alkGs can be both toxic and mutagenic, typically miscoding with thymine during DNA replication, producing GC → AT transition mutations.²⁶ Recently, two mutational signatures have been described in urothelial tumors from cattle that grazed on pastures with bracken fern and human cell lines treated with bracken fern extracts and ptaquiloside.²⁷ One signature contains mutations at GC base pairs and is thus potentially consistent with the formation of an *O*⁶-alkG adduct, while the second is defined by a preponderance of mutations at AT base pairs. The latter mutations may arise from already described PTQ-adenine adducts²⁰ but are also consistent with the formation of *O*⁴-alkT adducts, which are likely to be formed as well.

The relative amounts of *O*⁶-alkGs formed in DNA depend on the nature of the alkylating agent.²⁸ In this context, highly reactive or hard electrophiles²⁹ show increased levels of alkylation at guanine O6 compared to less reactive or soft electrophiles that preferentially react at the soft electrophilic N7 position. *N*-alkyl-nitrosoureas, that alkylate via hard electrophilic diazonium species, result in a typical ratio for ethylation on guanine O6 versus N7 of 0.65 and around 1.7 for larger secondary alkyls such as isopropyl.³⁰ Previously, the formation of an *O*⁶-alkG adduct following the reaction of PTQ dienone has been demonstrated for the ribonucleoside guanosine¹² but not for DNA. However, the formation of an *O*⁶-alkG in DNA following exposure to PTQ dienone would be consistent with the observed mutagenicity and carcinogenicity associated with exposure to PTQ dienone and PTQ. Furthermore, the genotoxicity of this putative adduct is likely to depend on its

ODN-1 (O^6 -PTBG (X) 23-Mer): 5' - GAA CTX CAG CTC CGT GCT GGC CC -3'
 ODN-2 (G 23-Mer): 5' - GAA CTG CAG CTC CGT GCT GGC CC -3'
 ODN-3 (30-Mer): 5' - CCT TTC CCG GGC CTT TCC TCT TCT CTT TCC -3'
 ODN-4 (comp 30-Mer): 3' - GGA AAG GGC CCG GAA AGG AGA AGA GAA AGG -5'
 ODN-5 (HEX comp 23-Mer): 3' - CTT GCC GTC GAG GCA CGA CCG GG HEX -5'
 ODN-6 (O^6 -MeG (Y) 23-Mer): 5' - GAA CTY CAG CTC CGT GCT GGC CC -3'




Figure 2. ODNs used and characterization of O^6 -PTBG-containing ODN: (A) RP-HPLC chromatogram of purified ODN-1, 12.5–25% MeCN in 0.1 M TEAA pH 7.0 over 30 min; (B) 20% denaturing PAGE stained with Sybr Gold; (C) ESI MS of ODN-1; theoretical mass = 7201.627 Da, experimental mass = 7201.302 Da; and (D) nucleoside composition analysis of ODN-1 5'-GAACT(O^6 -PTBG)CAGCTCCGTGCTGGCCC (see Table S1 in the Supporting Information).

repair by O^6 -methylguanine-DNA methyltransferase (MGMT). MGMT repairs many types of O^6 -alkGs in DNA via irreversible transfer of the alkyl group to Cys145.²⁶ However, we³¹ and others³² have shown that certain O^6 -alkG adducts are very poor substrates for MGMT. If such damage is not processed by other repair pathways, it is likely to persist in DNA and thereby be more harmful.

The objective of this study was to provide evidence for the first time that exposure to PTQ derived from bracken fern can form O^6 -alkG adducts in DNA. Since such adducts are likely to be carcinogenic, such characterization would provide a basis for the observed carcinogenicity resulting from PTQ exposure. We have also explored the potential harmful effects of adduct formation in humans by investigating the ability of the DNA damage reversal protein MGMT to repair such adducts.

MATERIALS AND METHODS

Chemicals, Reagents, and Equipment. All of the reagents were obtained from commercial suppliers and used without further purification. Ptaquiloside was isolated as described.¹¹ Dry solvents were obtained from the University of Sheffield Grubbs apparatus, and all anhydrous reactions were carried out in a flame-dried apparatus under N_2 using standard Schlenk techniques unless otherwise stated. Column chromatography was performed on silica gel for flash chromatography (30–70 μ m). Thin layer chromatography (TLC) was performed on precoated Merck silica gel 60 F254 aluminum backed plates. TLC chromatograms were visualized under UV (254 nm). NMR spectra were recorded on a Bruker AVANCE 3 HD 400 spectrometer, and chemical shifts are reported in δ values relative to tetramethylsilane as an external standard. J values are given in Hz. Mass spectrometry was

either performed by the University of Sheffield Mass Spectrometry Service using the method of positive electrospray ionization on a Agilent 1260 Infinity liquid chromatography instrument connected to an Agilent 6530 Q-ToF, using an Agilent Zorbax C18 2.1 mm \times 50 mm, 1.8 μ m column at a flow rate of 0.4 mL/min, or by the University of Sheffield Chemical and Biological Engineering department Orbitrap Exploris 240 LC-MS system using a Phenomenex Gemini C18 5 μ m 4.6 \times 250 mm column, with a flow rate of 0.75 mL/min. Analytical reverse phase high-performance liquid chromatography (RP-HPLC) was performed on a Transgenomic Wave 3500 HPLC system using a Phenomenex Gemini C18 5 μ m 4.6 \times 250 mm column, at 40 $^\circ$ C and a flow rate of 1 mL/min. UV detection was recorded at 260 nm unless specified otherwise. DNA synthesis was carried out using an Applied Biosystems Incorporated 394 DNA synthesizer using standard DNA.

Chemical Synthesis. The following were synthesized as described: pterosin B,³³ N^7 -methyl-2'-deoxyguanosine,³⁴ and O^6 -methyl-2'-deoxyguanosine.³⁵

O^6 -(Pterosin B)-2'-deoxyguanosine (O^6 -PTB-2'-deoxyguanosine) (5). O^6 -Mesitylenesulfonyl-3',5'-bis- O -(*t*-butyldimethylsilyl)-2'-deoxyguanosine (4)³⁵ (12.4 mg, 18 μ mol), pterosin B (10 mg, 46 μ mol, 2.5 equiv), and DABCO (8.2 mg, 73.4 μ mol, 4 equiv) were placed under Ar in a flask sealed with a rubber septum. Dry 1,2-DME (300 μ L) was then added, and the mixture was stirred for 1 h at room temperature (rt). DBU (11 μ L, 73 μ mol) was then added, and the mixture was stirred for 2 days, turning the white precipitate to a yellow solution. The solvent was then evaporated to give the O^6 -(pterosin B)-3',5'-bis- O -(*t*-butyldimethylsilyl)-2'-deoxyguanosine intermediate as a yellow oil. R_f (EtOAc) = 0.75, PTB: R_f (EtOAc) = 0.51.

The intermediate was redissolved in THF (300 μ L) and sealed with a rubber septum, TBAF in THF (1 M, 11.6 μ L, 40.3 μ mol) was added, and the mixture was stirred with an O/N mixture at rt. The solvent was evaporated, and the crude product was purified by RP-HPLC (5–65%




Figure 3. Nucleoside composition analysis of the PTQ dienone-treated DNA duplex: (A) RP-HPLC following enzymatic digestion of PTQ dienone-treated DNA (see the [Supporting Information](#) for details); (B) extracted ion chromatogram (XIC) of the PTQ dienone-treated DNA duplex following enzymatic digestion to nucleosides and XIC of *N*⁷-PTB-dG/*O*⁶-PTB-dG 468.2 [M + H]⁺ (*m/z*); (C) MS/MS spectrum of selected ion 468.2 [M + H]⁺ (*m/z*), LC retention time 18.18 min; (D) MS/MS spectrum of selected ion 468.2 [M + H]⁺ (*m/z*), LC retention time 29.52 min; (E) RP-HPLC analysis of the *O*⁶-PTB-dG standard; (F) XIC of the 468.2 [M + H]⁺ (*m/z*) *O*⁶-PTB-dG standard shown in panel E; (G) MS of the *O*⁶-PTB-dG standard; and (H) MS/MS spectrum *O*⁶-PTB-dG. This corresponds to that shown in panel D, confirming the identity of *O*⁶-PTB-dG from the nucleoside digest. In panels C, D, and H, the masses of 352.17 and 201.127 *m/z* values are obtained from expected fragmentation across the glycosidic bond and pterosis B moiety, respectively, as shown.

MeCN/water over 30 min) to afford pterosis B and the crude product as a white solid. The crude product was further purified by preparative TLC (10% MeOH/EtOAc) to afford the product (5) as a white solid (1.5 mg, 18%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.10 (s, 1H), 7.22 (s, 1H), 6.37 (s, 2H), 6.22 (dd, *J* = 7.8, 6.0 Hz, 1H), 5.27 (d, *J* = 4.0 Hz, 1H), 4.99 (t, *J* = 5.6 Hz, 1H), 4.51 (t, *J* = 7.4 Hz, 2H), 4.36 (dddd, *J* = 6.2, 4.0, 3.0, 2.6 Hz, 1H), 3.83 (ddd, *J* = 5.0, 4.7, 2.6 Hz, 1H), 3.58 (ddd, *J* = 11.6, 5.6, 5.0 Hz, 1H), 3.51 (ddd, *J* = 11.6, 5.6, 4.7 Hz, 1H), 3.24 (dd, *J* = 16.7, 7.7 Hz, 1H), 3.17 (t, *J* = 7.4 Hz, 2H), 2.68 (s, 3H), 2.66–2.54 (m, 3H), 2.49 (s, 3H), 2.22 (ddd, *J* = 13.0, 6.0, 3.0 Hz, 1H), 1.17 (d, *J* = 7.3 Hz, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆): δ 209.73, 160.59, 160.15, 154.39, 153.04, 144.91, 138.34, 137.54, 134.92, 131.90, 126.22, 114.40, 88.08, 83.25, 71.23, 64.54, 62.21, 55.39, 42.40, 33.66, 28.19, 21.35, 16.67, 13.71; *R*_f (10% MeOH/EtOAc) = 0.38, PTB: *R*_f (10% MeOH/EtOAc) = 0.82; HRMS *m/z*: (ESI⁺) [M + H]⁺ calcd for C₂₄H₄₉N₅O₅, 468.22541; found, 468.22344; HPLC retention time: 29.51 min, 3–75% MeCN in H₂O over 36 min.

Oligodeoxyribonucleotide (ODN) Methods. All of the ODNs (Figure 2) except for ODN-1 (containing *O*⁶-PTBG) were purchased from ATD-Bio purified by HPLC.

Synthesis of ODN-1. ODN-1 was prepared from the corresponding 2-amino-6-methylsulfonylpyrimidine (X)-containing sequence 23 mer ODN sequence (5'-GAA CTX CAG CTC CGT GCT GGC CC) that was synthesized as described.³¹ One controlled pore glass (CPG) column (1 μmol) of this 2-amino-6-methylsulfonylpyrimidine-containing ODN was dried in a desiccator before treatment with 10% DBU in dry MeCN (5 mL) for 3 min, and the column was then washed with MeCN (15 mL). The column was then dried by blowing argon through, and the CPG was then transferred into a Wheaton Screw-Top V-Vial (Sigma-Aldrich) (2 mL). A solution of pterosis B (10 mg) in 10% DBU/dry MeCN (500 μL) was then added to the vial which was flushed with argon, and the mixture was shaken for 5 days at rt. Concentrated aqueous ammonia solution (33%, 1 mL) was then added, and the mixture was shaken for a further 3 days at rt. The supernatant

was removed from the CPG beads, which were then washed with water ($3 \times 300 \mu\text{L}$). Unreacted pteroin B was then extracted using ethyl acetate ($3 \times 3 \text{ mL}$). ODN-1 was purified by RP-HPLC using a Phenomenex Gemini C18 $5 \mu\text{m}$ $4.6 \text{ mm} \times 250 \text{ mm}$ column at a flow rate of 1 mL/min . Gradient 12.5–25% MeCN in 0.1 M TEAA , pH 7.0 over 30 min. Retention time 20.0 min. ESI-MS Calcd 7201.627, found 7201.302.

Nucleoside Composition Analysis of ODN-1. ODN-1 was digested using the Nucleoside Digestion Mix ($10 \mu\text{L}$) from New England BioLabs in Milli-Q water ($160 \mu\text{L}$) and 10X Nucleoside digestion mix buffer ($20 \mu\text{L}$) and then incubated at $37 \text{ }^\circ\text{C}$ for 1 h. The mixture was then analyzed using RP-HPLC using a Phenomenex Gemini C18 $5 \mu\text{m}$ $4.6 \text{ mm} \times 250 \text{ mm}$ column, at $40 \text{ }^\circ\text{C}$ and a flow rate of 1 mL/min . The gradient used was 3–75% MeCN/ H_2O over 36 min (Figure 2D) in the main text. Nucleoside composition of ODN-1 was calculated from the peak areas of the respective nucleosides in the HPLC trace (Table S1 in the Supporting Information).

Preparation of PTQ Dienone. To a sample of PTQ (4 mg) was added 0.02 M aqueous Na_2CO_3 (2 mL), which was left stirring for 20 min at rt. PTQ dienone was extracted using a solution of 2:1 hexane/diethyl ether ($3 \times 3 \text{ mL}$). Formation of PTQ dienone was confirmed by HPLC and MS (see Figure S1 in the Supporting Information). The organic layer was passed through a plug of Na_2CO_3 before rotary evaporation.

Reaction of PTQ Dienone with Duplex DNA. PTQ dienone (obtained as described above) was redissolved in MeCN ($250 \mu\text{L}$) and added to 100 nmol of an annealed duplex of ODN-3 and ODN-4 in 0.1 M phosphate buffer ($750 \mu\text{L}$, pH 7.5). The mixture was then incubated at $37 \text{ }^\circ\text{C}$ for 2 h. Unreacted pteroin B was removed by extraction into EtOAc ($3 \times 500 \mu\text{L}$), before desalting using a Cytiva NAP-10 gel filtration column. Ten micrograms (0.53 nmol , $10 \mu\text{L}$) of the dienone-exposed duplex DNA was then digested using the Nucleoside Digestion Mix ($10 \mu\text{L}$) from New England BioLabs in Milli-Q water ($160 \mu\text{L}$) and 10X Nucleoside digestion mix buffer and then incubated at $37 \text{ }^\circ\text{C}$ for 1 h. Analysis of the constituent nucleosides was undertaken on an Orbitrap Exploris 240 LC-MS system without any further purification. Nucleoside composition of the PTQ dienone-treated DNA duplex was calculated (see Table S2 in the Supporting Information) from the peak areas of the respective nucleosides in the HPLC trace (Figure 3). Analysis is shown in Figure 2.

Recognition of the O^6 -PTBG Adduct by MGMT and At11. *MGMT Recognition of O^6 -PTBG:* *PstI Restriction Endonuclease Assays.* Reaction mixtures ($20 \mu\text{L}$) contained 10 pM MGMT protein and 50 fmol 23mer O^6 -alkylguanine (ODN-1 or ODN-6): 5'-HEX-labeled complement ODN-5 duplex in 50 mM Tris-HCl, pH 8.3, 3 mM DTT, and 1 mM EDTA. Reactions that were subjected to incubations were carried out at $37 \text{ }^\circ\text{C}$ for 1 h, first with MGMT and second with *PstI*. Samples were analyzed by PAGE (20%) using Typhoon 9200, Variable Mode Imager by Amersham Biosciences.

MGMT Recognition of O^6 -PTBG: Determination of IC_{50} Values for the O^6 -AlkG ODNs. The assay used the method of Watson et al.³⁶ All radioactive MGMT assays were completed with ds DNA, and each incubation was completed at $37 \text{ }^\circ\text{C}$ for 90 min. Scintillation was measured on a Tri Carb 1900 TR Liquid Scintillation Analyzer by Packard over 5 min periods for each sample, and the IC_{50} was calculated from these values (Figure S6, Supporting Information).


At11 Recognition of O^6 -PTBG-Containing ODNs Using EMSA. Reaction mixtures ($20 \mu\text{L}$) contained 50 fmol 23mer O^6 -alkylguanine (ODN-1 or ODN-6): 5'-HEX-labeled complement oligonucleotide duplex (ODN-5) in 50 mM Tris-HCl, pH 8.3, 3 mM DTT, and 1 mM EDTA and varying concentrations of At11-MBP or At11 proteins. Reactions were incubated at $37 \text{ }^\circ\text{C}$ for 1 h and then analyzed by native PAGE (15%) using Typhoon 9200, Variable Mode Imager by Amersham Biosciences.

RESULTS AND DISCUSSION

To characterize and quantify DNA damage derived from exposure to PTQ dienone, we planned to identify constituent nucleosides following enzymatic digestion. We, therefore,

synthesized a nucleoside standard of O^6 -PTBdG (5) by following a literature procedure,³⁵ reacting 3',5'-di-*O*-TBDMS-protected 6-mesitylsulfonyl-2'-deoxyguanosine (4) with PTB,³³ DABCO, and DBU in DME (Scheme 2).

Scheme 2. Synthesis of the O^6 -PTBdG Nucleoside Standard (5)



Subsequent removal of the TBDMS protecting groups with TBAF in THF and purification by RP-HPLC followed by preparative TLC afforded nucleoside standard 5, whose structure was confirmed by MS and NMR.

To establish that complete enzymatic digestion of DNA containing O^6 -PTBdG (5) to constituent nucleosides could be achieved, we prepared a 23mer oligodeoxyribonucleotide (ODN-1) (5'-GAA CT(O^6 -PTBG) CAG CTC CGT GCT GGC CC). Thus, an ODN precursor containing the convertible base 2-amino-6-methylsulfonyl-purine³¹ was reacted with PTB³³ in DBU/acetonitrile. Following deprotection with aqueous ammonia, desalting, and purification by RP-HPLC, MS analysis revealed that the ODN mass was 40 Da higher than predicted. This suggested that an acrylonitrile adduct formed during the removal of the cyanoethyl protecting groups. In a repeated synthesis, the desired ODN was obtained successfully by including an initial brief treatment of the support-bound ODN with DBU/acetonitrile prior to the displacement reaction. ESI MS confirmed the correct mass of 7201.6 for ODN-1 (Figure 2). Enzymatic digestion of ODN-1 to constituent nucleosides followed by analysis using RP-HPLC confirmed the presence of the modified nucleoside O^6 -PTB in the expected ratio with the other nucleosides (Figure 2).

PTQ dienone was prepared from PTQ following the previous literature.¹² Thus, PTQ was subject to a brief treatment with 0.02 M aq sodium carbonate before extraction into 2:1 hexane/diethyl ether. Formation of PTQ dienone was confirmed by RP-HPLC and ESI-MS spectra, which revealed two products of PTQ decomposition: PTQ dienone as a later-eluting, less polar product together with PTB derived from partial hydrolysis (Figure S1). A 30-mer DNA duplex ODN-3/ODN-4 (100 nmol) was then treated with approximately 2 mg of PTQ dienone at $37 \text{ }^\circ\text{C}$ for 2 h. The DNA was then desalted and subjected to enzymatic digestion, and the mixture was analyzed by LC-MS (Figure 3). This revealed a deoxyribonucleoside with a retention time identical to that of the O^6 -PTBdG standard (5) and the expected mass.

Further confirmation was made by comparison of MS/MS spectra obtained for the O^6 -PTBdG standard and corresponding species in the enzymatic digest (Figure 3D,G, respectively). This to the best of our knowledge is the first identification of the formation of an O^6 -PTB adduct in DNA following treatment with PTQ dienone. An earlier eluting peak (approximately 18 min) with the same m/z value as that of O^6 -PTBdG was also identified in the HPLC chromatogram of the nucleoside digest (Figure 3A). Using standards of O^6 -methylG (O^6 -MedG) and N^7 -methylG (N^7 -MedG), we ascertained that the latter nucleoside eluted significantly earlier under the same HPLC

conditions (Figure S3). We, therefore, assigned the earlier eluting PTBdG nucleoside observed following HPLC analysis of the nucleoside digest to the N^7 -adduct. Although this component might derive from alkylation at another site on guanine such as N2, such adducts have not been identified in previous studies that have explored the reactivity of PTQ and its dienone with nucleosides and nucleic acids.^{12,20} Furthermore, products derived from N2 alkylation would be expected to have similar LC characteristics to O^6 -PTBdG, unlike charged more polar N^7 -adducts, which would elute significantly earlier by RP-HPLC, as we observe here. Using the known extinction coefficients,¹² we calculated (Table S2) the relative amounts of O^6 -PTBdG and N^7 -PTBdG formed following treatment of the DNA duplex with PTQ dienone (Table 1). The ratio of O^6/N^7 alkylation observed is approximately 1.4 and similar to values previously determined in reactions of hard electrophiles with guanine in DNA.^{28,30}

Table 1. Amount of Guanine Adducts after Treatment of Duplex DNA with PTQ Dienone

nucleoside	area ^a	corrected area	% detected
O^6 -PTBdG	1.00	0.25	0.7
N^7 -PTBdG	0.80	0.18	0.51
dG	55.30	34.56	98.57

^aCalculated from HPLC chromatogram Figure 3A. See the Supporting Information (Table S2).

Although O^6 -alkGs are known to be toxic, mutagenic, and carcinogenic, their ability to induce such effects can be determined by how efficiently they are repaired by MGMT.²⁶ Previously, we and others have shown that certain O^6 -alkGs such as 2-hydroxyethyl³¹ and 4-(3-pyridyl)-4-oxobutyl³² are rather poor substrates for MGMT. To assess the ability of MGMT to

repair O^6 -PTBG, we annealed ODN-1 to an unmodified complementary duplex, ODN-5, creating a *Pst*I restriction endonuclease recognition sequence encompassing the adduct. A duplex containing O^6 -MeG in the *Pst*I site was resistant to cleavage by *Pst*I, but following incubation with MGMT and then *Pst*I, complete cleavage of the duplex was observed (Figure 4). In contrast, when the O^6 -PTBG-containing sequence was treated in the same way, no digestion of the DNA was observed, suggesting that the adduct is not a substrate for MGMT under the assay conditions used.

Further assessment of the ability of MGMT to repair O^6 -PTBG was obtained using a radioisotope-based competition assay,³⁶ in which MGMT is first incubated with lesion-containing ODNs and residual activity is quantified after subsequent incubation with DNA containing tritiated O^6 -MeG. In this assay, the IC_{50} (ODN concentration resulting in 50% inactivation of MGMT) for the O^6 -MeG and O^6 -PTBG duplexes was ~ 2 nM and ~ 200 nM, respectively (Figure S11). This indicates that O^6 -PTBG is a poor MGMT substrate relative to O^6 -MeG, possibly resulting in the accumulation of this damage with prolonged exposures. In this context, earlier studies have shown that MGMT and the *Escherichia coli* alkyltransferase, AGT, repaired a series of O^6 -alkGs in DNA in vitro at different rates, but these were generally slower as the size and complexity of the alkyl group increased.³⁷ In various human and Chinese hamster cell lines, repair of higher O^6 -alkGs in DNA has been reported to be dependent upon NER^{38,39} or both MGMT and NER.^{39,40} The potential genotoxicity of a poor substrate for MGMT will thus depend on how well it is recognized and processed by other repair systems in any particular organism. Indeed, the antitumor drug, Illudin S, is structurally related to PTQ, and the damage it introduces into DNA is processed by transcription- or replication-coupled NER.⁴¹




Figure 4. MGMT shows lack of repair of O^6 -PTBG: (A) *Pst*I recognition sequence containing O^6 -alkG in the ODN duplex; (B) MGMT repair (alkyl transfer) results in an unmodified sequence that is cleaved by *Pst*I; (C) *Pst*I does not hydrolyze duplex DNA containing O^6 -alkG in its recognition sequence; and (D) analysis of ODN duplexes by 20% PAGE following treatment with MGMT and *Pst*I: G represents unmodified duplex, PTBG indicates the ODN duplex containing O^6 -PTBG, Me indicates the ODN duplex containing O^6 -MeG.

We also investigated the *Schizosaccharomyces pombe* protein Atl1, which recognizes O^6 -alkGs in ODNs and binds with high affinity but, unlike MGMT, does not transfer the alkyl group.⁴² As shown in Figure 5, titrating Atl1 protein with ODNs that




Figure 5. EMSA of ds 23mer ODNs following incubation with increasing concentrations of MBP-Atl1. Duplexes were of unmodified guanine (G; ODNs 2 + 5 lanes 1–5), O^6 -PTBG (ODNs 1 + 5 lanes 7–11), and O^6 -MeG (ODNs 5 + 6). Lanes 13–17. The migration positions of the excess complement, unbound duplex, and bound duplex are shown.

contain either O^6 -PTBG or O^6 -MeG results in a concentration-dependent formation of a protein–DNA complex, seen as a slower-running band on native PAGE. Very little binding to the G control duplex was seen, and with the O^6 -PTBG ODN, almost all the duplex was shifted, whereas some residual unbound ODN was seen with the O^6 -MeG duplex, indicating stronger binding to the former than to the latter. This confirms that O^6 -PTBG is recognized and bound by Atl1, in common with ODNs containing all other O^6 -alkGs that we have previously tested.⁴³

The exposure of DNA to PTQ dienone derived from the bracken carcinogen PTQ results in the formation of a variety of DNA adducts. Here, we have synthesized an ODN containing the O^6 -guanine adduct derived from this reaction, namely, O^6 -PTBG, and we have shown for the first time that exposure of DNA to PTQ dienone results in the formation of this adduct. In common with other O^6 -alkGs, O^6 -PTBG is likely to be mutagenic and possibly toxic. Furthermore, since it is very poorly repaired by MGMT, it may be persistent and more deleterious. The carcinogenicity of bracken and PTQ could, therefore, be attributed to the formation of O^6 -PTBG in DNA.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jafc.4c07187>.

Supporting figures, MS spectra of oligodeoxyribonucleotides, and NMR spectra of compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Author

David M. Williams – Centre for Chemical Biology, Department of Chemistry, Institute for Nucleic Acids, University of Sheffield, Sheffield S3 7HF, U.K.; orcid.org/0000-0002-5618-182X; Email: d.m.williams@sheffield.ac.uk

Authors

Fourat Keskin – Centre for Chemical Biology, Department of Chemistry, Institute for Nucleic Acids, University of Sheffield, Sheffield S3 7HF, U.K.

Hannah Noone – Centre for Chemical Biology, Department of Chemistry, Institute for Nucleic Acids, University of Sheffield, Sheffield S3 7HF, U.K.; Present Address: University Hospitals of North Midlands NHS Trust, UK

Mark J. Dickman – Department of Chemical and Biological Engineering, University of Sheffield, Sheffield S1 3JD, U.K.; orcid.org/0000-0002-9236-0788

Esther Allen – Centre for Chemical Biology, Department of Chemistry, Institute for Nucleic Acids, University of Sheffield, Sheffield S3 7HF, U.K.

William D. Mulcrone – Centre for Chemical Biology, Department of Chemistry, Institute for Nucleic Acids, University of Sheffield, Sheffield S3 7HF, U.K.

Lars Holm Rasmussen – Novonosis, Microbe & Culture Research, Hørsholm DK-2970, Denmark

Hans Christian Bruun Hansen – Department of Plant and Environmental Sciences, University of Copenhagen, Frederiksberg C DK-1871, Denmark; orcid.org/0000-0002-8617-2393

Peter J. O'Connor – Centre for Occupational and Environmental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, U.K.

Andrew C. Povey – Centre for Occupational and Environmental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, U.K.

Geoffrey P. Margison – Centre for Occupational and Environmental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, U.K.

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.jafc.4c07187>

Author Contributions

The manuscript was written through contributions of all authors.

Funding

This work was supported by research funds from an EPSRC UK grant to EA/DW (EP/P010075/1), an EPSRC studentship (FK), and a studentship funded by EPSRC/QuantuMDx Ltd. (HN).

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We dedicate this manuscript to the memory of our mentor and friend Peter John O'Connor (16th May 1932–11th April 2024), whose longstanding interest in all things bracken catalyzed this work and so much other cancer research.

■ ABBREVIATIONS

ESI MS, electrospray ionization mass spectrometry; MGMT, O^6 -methylguanine-DNA-methyltransferase; N^3 -alkA, N^3 -alkyladenine; N^7 -alkG, N^7 -alkylguanine; O^6 -alkG, O^6 -alkylguanine; ODN, oligodeoxyribonucleotide; PTB, pterosisinB; PTQ, ptaquiloside; RP-HPLC, reversed phase high-performance

liquid chromatography; TBDMS, *tert*-butyldimethylsilyl; TEAA, triethylammonium acetate

REFERENCES

- (1) Invasive species compendium: *Pteridium aquilinum* (bracken). Available at: <http://www.cabi.org/isc/datasheet/45596> (accessed July 18, 2024).
- (2) (a) Potter, D. M.; Baird, M. S. Carcinogenic Effects of Ptaquiloside in Bracken Fern and Related Compounds. *Br. J. Cancer* **2000**, *83*, 914–920. (b) Yamada, K.; Ojika, M.; Kigoshi, H. Isolation, Chemistry, and Biochemistry of Ptaquiloside, a Bracken Carcinogen. *Angew. Chem., Int. Ed.* **1998**, *37*, 1818–1826. (c) Vetter, J. A. Biological Hazard of Our Age: Bracken Fern [*Pteridium Aquilinum* (L.) Kuhn] - A Review. *Acta Vet. Hung.* **2009**, *57*, 183–196. (d) Gil da Costa, R. M.; Bastos, M. M. S. M.; Oliveira, P. A.; Lopes, C. Bracken-Associated Human and Animal Health Hazards: Chemical, Biological and Pathological Evidence. *J. Hazard. Mater.* **2012**, *203*–204, 1–12. (e) Clauson-Kaas, F.; Ramwell, C.; Hansen, H. C. B.; Strobel, B. W. Ptaquiloside from bracken in stream water at base flow and during storm events. *Water Res.* **2016**, *106*, 155–162. (f) O'Connor, P. J.; Alonso-Amelot, M. E.; Roberts, S. A.; Povey, A. C. The Role of Bracken Fern Illudanes in Bracken Fern-Induced Toxicities. *Mutat. Res. Rev. Mutat. Res.* **2019**, *782*, 108276. (g) Skrbic, N.; Kisielius, V.; Pedersen, A.-K.; Christensen, S. C. B.; Hedegaard, M. J.; Hansen, H. C. B.; Rasmussen, L. H. Occurrence of carcinogenic illudane glycosides in drinking water wells. *Environ. Sci. Eur.* **2021**, *33*, 44. (h) Garcia-Jorgensen, D. B.; Diamantopoulos, E.; Kisielius, V.; Rosenfeld, M.; Rasmussen, L. H.; Strobel, B. W.; Hansen, H. C. B. Bracken growth, toxin production and transfer from plant to soil: a 2-year monitoring study. *Environ. Sci. Eur.* **2021**, *33*, 45. (i) Vetter, J. The Norsesquiterpene Glycoside Ptaquiloside as a Poisonous, Carcinogenic Component of Certain Ferns. *Molecules* **2022**, *27*, 6662. (j) Kisielius, V.; Drejer, M.; Dornhoff, J. K.; Mrkajic, N. S.; Lindqvist, D. N.; Hansen, H. C. B.; Rasmussen, L. H. Occurrence and stability of ptesculentoside, caudatoside and ptaquiloside in surface waters. *Environ. Sci.:Processes Impacts* **2022**, *24*, 277–289. (k) Park, H.; Cho, Y.; Lee, J. E.; Lee, K. M.; Kim, H. J.; Lee, J.; Bahn, Y.-S.; Son, J. Evaluation and Monitoring of the Natural Toxin Ptaquiloside in Bracken Fern, Meat, and Dairy Products. *Toxins* **2023**, *15*, 231. (l) Gil Da Costa, R. M.; Povey, A.; Medeiros-Fonseca, B.; Ramwell, C.; O'Driscoll, C.; Williams, D.; Hansen, H. C. B.; Rasmussen, L. H.; Fletcher, M. T.; O'Connor, P.; Bradshaw, R. H. W.; Robinson, R.; Mason, J. Sixty Years of Research on Bracken Fern (*Pteridium* Spp.) Toxins: Environmental Exposure, Health Risks and Recommendations for Bracken Fern Control. *Environ. Res.* **2024**, *257*, 119274. (m) Malík, M.; Mika, O. J.; Navrátilová, Z.; Kili, U. K.; Tlustoš, P.; Patocka, J. Health and Environmental Hazards of the Toxic *Pteridium aquilinum* (L.) Kuhn (Bracken Fern). *Plants* **2024**, *13*, 18.
- (3) Evans, I. A.; Mason, J. Carcinogenic Activity of Bracken. *Nature* **1965**, *208*, 913–914.
- (4) (a) Niwa, H.; Ojika, M.; Wakamatsu, K.; Yamada, K.; Hirono, I.; Matsushita, K. Ptaquiloside, a Novel Norsesquiterpene Glucoside from Bracken, *Pteridium Aquilinum* Var. *Latiusculum*. *Tetrahedron Lett.* **1983**, *24*, 4117–4120. (b) van Der Hoeven, J. C.; Lagerweij, W. J.; Posthumus, M. A.; Van Veldhuizen, A.; Holterman, H. A. J.; Aquilide, A. Aquilide A, a new mutagenic compound isolated from bracken fern (*Pteridium aquilinum* (L.) Kuhn). *Carcinogenesis* **1983**, *4*, 1587–1590.
- (5) (a) Hirono, I.; Ogino, H.; Fujimoto, M.; Yamada, K.; Yoshida, Y.; Ikagawa, M.; Okumura, M. Induction of Tumors in ACI Rats Given a Diet Containing Ptaquiloside, a Bracken Carcinogen. *J. Natl. Cancer Inst.* **1987**, *79*, 1143–1149. (b) Hirono, I.; Aiso, S.; Yamaji, T.; Mori, H.; Yamada, K.; Niwa, H.; Ojika, M.; Wakamatsu, K.; Kiooshi, H.; Niiyama, K.; Uosaki, Y. Carcinogenicity in Rats of Ptaquiloside Isolated from Bracken. *Gann* **1984**, *75*, 833–836.
- (6) (a) Castillo, U. F.; Wilkins, A. L.; Lauren, D. R.; Smith, B. L.; Towers, N. R.; Alonso-Amelot, M. E.; Jaimes-Espinoza, R. Isoptaquiloside and Caudatoside, Illudane-Type Sesquiterpene Glucosides from *Pteridium Aquilinum* Var. *Caudatum*. *Phytochemistry* **1997**, *44*, 901–906. (b) Fletcher, M. T.; Hayes, P. Y.; Somerville, M. J.; De Voss, J. J.; Ptesculentoside, J. J. a Novel Norsesquiterpene Glucoside from the Australian Bracken Fern *Pteridium Esculentum*. *Tetrahedron Lett.* **2010**, *51*, 1997–1999.
- (7) (a) Alonso-Amelot, M. E.; Castillo, U.; De Jongh, F. Passage of the Bracken Fern Carcinogen Ptaquiloside into Bovine Milk. *Lait* **1993**, *73*, 323–332. (b) Alonso-Amelot, M. E.; Castillo, U.; Smith, B. L.; Lauren, D. R. Bracken Ptaquiloside in Milk. *Nature* **1996**, *382*, 587. (c) Alonso-Amelot, M. E.; Avendaño, M. Human Carcinogenesis and Bracken Fern: A Review of the Evidence. *Curr. Med. Chem.* **2002**, *9*, 675–686. (d) Fletcher, M. T.; Reichmann, K. G.; Brock, I. J.; McKenzie, R. A.; Blaney, B. J. Residue Potential of Norsesquiterpene Glycosides in Tissues of Cattle Fed Austral Bracken (*Pteridium Esculentum*). *J. Agric. Food Chem.* **2011**, *59*, 8518–8523. (e) Virgilio, A.; Sinisi, A.; Russo, V.; Gerardo, S.; Santoro, A.; Galeone, A.; Tagliatalata-Scafati, O.; Roperto, F. Ptaquiloside, the Major Carcinogen of Bracken Fern, in the Pooled Raw Milk of Healthy Sheep and Goats: An Underestimated, Global Concern of Food Safety. *J. Agric. Food Chem.* **2015**, *63*, 4886–4892.
- (8) (a) Marlière, C. A.; Santos, R. C.; Galvão, M. A. M.; Soares, J. F.; Evangelista, C. L. M.; Gomes, R. Q. F. Ingestão de Broto de Samambaia e Risco de Câncer de Esôfago e Estômago Na Região de Ouro Preto, MG. *Rev. Bras. Cancerol.* **1998**, *44*, 225–229. (b) Hirono, I.; Ito, M.; Yagyū, S.; Haga, M.; Wakamatsu, K.; Kishikawa, T.; Nishikawa, O.; Yamada, K.; Ojika, M.; Kigoshi, H. Reproduction of Progressive Retinal Degeneration (Bright Blindness) in Sheep by Administration of Ptaquiloside Contained in Bracken. *J. Vet. Med. Sci.* **1993**, *55*, 979–983. (c) Liu, Y.; Wujisguleng, W.; Long, C. Food Uses of Ferns in China: A Review. *Acta Soc. Bot. Pol.* **2012**, *81*, 263–270.
- (9) Rasmussen, L. H.; Schmidt, B.; Sheffield, E. Ptaquiloside in bracken spores from Britain. *Chemosphere* **2013**, *90*, 2539–2541.
- (10) IARC. *IARC Monographs on the Identification of Carcinogenic Hazards to Humans*, 1986; Vol. 40, pp 47–65.
- (11) Kisielius, V.; Lindqvist, D. N.; Thygesen, M. B.; Rodamer, M.; Hansen, H. C. B.; Rasmussen, L. H. Fast LC-MS Quantification of Ptesculentoside, Caudatoside, Ptaquiloside and Corresponding Pterosins in Bracken Ferns. *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.* **2020**, *1138*, 121966.
- (12) Ojika, M.; Wakamatsu, K.; Niwa, H.; Yamada, K. Ptaquiloside, a Potent Carcinogen Isolated from Bracken Fern *Pteridium aquilinum* Var. *Latiusculum*: Structure Elucidation Based on Chemical and Spectral Evidence, and Reactions with Amino Acids, Nucleosides, and Nucleotides. *Tetrahedron* **1987**, *43*, 5261–5274.
- (13) Ayala-Luis, K. B.; Hansen, P. B.; Rasmussen, L. H.; Hansen, H. C. B. Kinetics of Ptaquiloside Hydrolysis in Aqueous Solution. *Environ. Toxicol. Chem.* **2006**, *25*, 2623–2629.
- (14) Ríos-Gutiérrez, M.; Domingo, L. R.; Alonso-Amelot, M. E. A DFT Study of the Conversion of Ptaquiloside, a Bracken Fern Carcinogen, to Pterosin B in Neutral and Acidic Aqueous Medium. *ChemistrySelect* **2017**, *2*, 8178–8186.
- (15) Ojika, M.; Sugimoto, K.; Okazaki, T.; Yamada, K. Modification and Cleavage of DNA by Ptaquiloside. A New Potent Carcinogen Isolated from Bracken Fern. *J. Chem. Soc. Chem. Commun.* **1989**, 1775.
- (16) Nagao, T.; Saito, K.; Hirayama, E.; Uchikoshi, K.; Koyama, K.; Natori, S.; Morisaki, N.; Iwasaki, S.; Matsushima, T. Mutagenicity of Ptaquiloside, the Carcinogen in Bracken, and Its Related Illudane-Type Sesquiterpenes I. Mutagenicity in *Salmonella Typhimurium*. *Mutat. Res. Fund Mol. Mech. Mutagen* **1989**, *215*, 173–178.
- (17) Shahin, M.; Smith, B. L.; Worrall, S.; Moore, M. R.; Seawright, A. A.; Prakash, A. S. Bracken Fern Carcinogenesis: Multiple Intravenous Doses of Activated Ptaquiloside Induce DNA Adducts, Monocytosis, Increased TNF α Levels, and Mammary Gland Carcinoma in Rats. *Biochem. Biophys. Res. Commun.* **1998**, *244*, 192–197.
- (18) Macon, J. B.; Wolfenden, R. 1-Methyladenosine. Dimroth Rearrangement and Reversible Reduction. *Biochemistry* **1968**, *7*, 3453–3458.
- (19) (a) Beranek, D. T. Distribution of Methyl and Ethyl Adducts Following Alkylation with Monofunctional Alkylating Agents. *Mutat. Res. Fund Mol. Mech. Mutagen* **1990**, *231*, 11–30. and references therein (b) Drablos, F.; Feyzi, E.; Aas, P. A.; Vaagbø, C. B.; Kavli, B.; Bratlie, M. S.; Peña-Díaz, J.; Otterlei, M.; Slupphaug, G.; Krokan, H. E.

Alkylation Damage in DNA and RNA—Repair Mechanisms and Medical Significance. *DNA Repair* **2004**, *3*, 1389–1407.

(20) Kushida, T.; Uesugi, M.; Sugiura, Y.; Kigoshi, H.; Tanaka, H.; Hirokawa, J.; Ojika, M.; Yamada, K. DNA Damage by Ptaquiloside, a Potent Bracken Carcinogen: Detection of Selective Strand Breaks and Identification of DNA Cleavage Products. *J. Am. Chem. Soc.* **1994**, *116*, 479–486.

(21) Chetsanga, C. J.; Lindahl, T. Release of 7-Methylguanine Residues Whose Imidazole Rings Have Been Opened from Damaged DNA by a DNA Glycosylase from *Escherichia Coli*. *Nucleic Acids Res.* **1979**, *6*, 3673–3684.

(22) Engelward, B. P.; Allan, J. M.; Dreslin, A. J.; Kelly, J. D.; Wu, M. M.; Gold, B.; Samson, L. D. A Chemical and Genetic Approach Together Define the Biological Consequences of 3-Methyladenine Lesions in the Mammalian Genome. *J. Biol. Chem.* **1998**, *273*, 5412–5418.

(23) Singer, B.; Grunberger, D. *Molecular Biology of Mutagens and Carcinogens*; Plenum Press: New York, 1983.

(24) Schaaper, R. M.; Loeb, L. A. Depurination Causes Mutations in SOS-Induced Cells. *Proc. Natl. Acad. Sci. U.S.A.* **1981**, *78*, 1773–1777.

(25) Yang, Y.; Nikolich, D.; Swanson, S. M.; van Breemen, R. B. Quantitative Determination of N7-methyldeoxyguanosine and O6-methyldeoxyguanosine in DNA by LC-UV-MS-MS. *Anal. Chem.* **2002**, *74*, 5376–5382.

(26) Margison, G. P.; Santibañez Koref, M. F.; Povey, A. C. Mechanisms of Carcinogenicity/Chemotherapy by O⁶-Methylguanine. *Mutagenesis* **2002**, *17*, 483–487.

(27) Wong, K.; Abascal, F.; Ludwig, L.; Aupperle-Lellbach, H.; Grassinger, J.; Wright, C. W.; Allison, S. J.; Pinder, E.; Phillips, R. M.; Romero, L. P.; et al. Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer. *Genome Biol.* **2023**, *24*, 191.

(28) Beranek, D. T.; Weis, C. C.; Swenson, D. H. A Comprehensive Quantitative Analysis of Methylated and Ethylated DNA Using High Pressure Liquid Chromatography. *Carcinogenesis* **1980**, *1*, 595–606.

(29) Pearson, R. G. Hard and Soft Acids and Bases. *J. Am. Chem. Soc.* **1963**, *85*, 3533–3539.

(30) (a) Saffhill, R.; Margison, G. P.; O'Connor, P. J. Mechanisms of Carcinogenesis Induced by Alkylating Agents. *Biochim. Biophys. Acta, Rev. Cancer* **1985**, *823*, 111–145. (b) O'Connor, P. J. Interaction of Chemical Carcinogens with Macromolecules. *J. Cancer Res. Clin. Oncol.* **1981**, *99*, 167–186.

(31) Shibata, T.; Glynn, N.; McMurry, T. B. H.; McElhinney, R. S.; Margison, G. P.; Williams, D. M. Novel Synthesis of O6-Alkylguanine Containing Oligodeoxyribonucleotides as Substrates for the Human DNA Repair Protein, O⁶-Methylguanine DNA Methyltransferase (MGMT). *Nucleic Acids Res.* **2006**, *34*, 1884–1891.

(32) (a) Coulter, R.; Blandino, M.; Tomlinson, J. M.; Pauly, G. T.; Krajewska, M.; Moschel, R. C.; Peterson, L. A.; Pegg, A. E.; Spratt, T. E. Differences in the Rate of Repair of O⁶-Alkylguanines in Different Sequence Contexts by O⁶-Alkylguanine-DNA Alkyltransferase. *Chem. Res. Toxicol.* **2007**, *20*, 1966–1971. (b) Du, H.; Wang, P.; Li, L.; Wang, Y. Repair and Translesion Synthesis of O⁶-Alkylguanine DNA Lesions in Human Cells. *J. Biol. Chem.* **2019**, *294*, 11144–11153.

(33) Dexter, H. R.; Allen, E.; Williams, D. M. A Concise Stereoselective Synthesis of Pterosin B. *Tetrahedron Lett.* **2018**, *59*, 4323–4325.

(34) Ashworth, D. J.; Baird, W. M.; Chang, J.; Ciupek, J. D.; Busch, K. L.; Cooks, R. G. Chemical Modification of Nucleic Acids. Methylation of Calf Thymus DNA Investigated by Mass Spectrometry and Liquid Chromatography. *Biol. Mass Spectrom.* **1985**, *12*, 309–318.

(35) Lakshman, M. K.; Ngassa, F. N.; Keeler, J. C.; Dinh, Y. Q. V.; Hilmer, J. H.; Russon, L. M. Facile Synthesis of O⁶-Alkyl-, O⁶-Aryl- and Diaminopurine Nucleosides from 2'-Deoxyguanosine. *Org. Lett.* **2000**, *2*, 927–930.

(36) Watson, A. J.; Margison, G. P. O⁶-Alkylguanine-DNA Alkyltransferase Assay. In *DNA Repair Protocols-Prokaryotic Systems: Methods in Molecular Biology*; Humana Press: NJ, 2000; pp 49–61.

(37) Morimoto, K.; Dolan, M. E.; Scicchitano, D.; Pegg, A. E. Repair of O⁶-Propylguanine and O⁶-Butylguanine in DNA by O⁶-Alkylgua-

nine-DNA Alkyltransferases from Rat Liver and *E. Coli*. *Carcinogenesis* **1985**, *6*, 1027–1031.

(38) (a) Simon, L.; Hazard, R. M.; Maher, V. M.; McCormick, J. J. Enhanced Cell Killing and Mutagenesis by Ethylnitrosourea in Xeroderma Pigmentosum Cells. *Carcinogenesis* **1981**, *2*, 567–570. (b) Boyle, J. M.; Saffhill, R.; Margison, G. P.; Fox, M. A. Comparison of Cell Survival, Mutation and Persistence of Putative Promutagenic Lesions in Chinese Hamster Cells Exposed to BNU or MNU. *Carcinogenesis* **1986**, *7*, 1981–1985. (c) Boyle, J. M.; Durrant, L. G.; Wild, C. P.; Saffhill, R.; Margison, G. P. Genetic Evidence for Nucleotide Excision Repair of O⁶-Alkylguanine in Mammalian Cells. *J. Cell Sci.* **1987**, *1987*, 147–160. (d) Bignami, M.; Dogliotti, E.; Aquilina, G.; Zijno, A.; Wild, C. P.; Montesano, R. O⁶-Methyltransferase-Deficient and -Proficient CHO Cells Differ in Their Responses to Ethyl- and Methyl-Nitrosourea-Induced DNA Alkylation. *Carcinogenesis* **1989**, *10*, 1329–1332.

(39) Boyle, J. M.; Margison, G. P.; Saffhill, R. Evidence for the excision repair of O⁶-n-butyldeoxyguanosine in human cells. *Carcinogenesis* **1986**, *7*, 1987–1990.

(40) (a) Bronstein, S. M.; Cochrane, J. E.; Craft, T. R.; Swenberg, J. A.; Skopek, T. R. Toxicity, Mutagenicity, and Mutational Spectra of N-Ethyl-N-nitrosourea in Human Cell Lines with Different DNA Repair Phenotypes. *Cancer Res.* **1991**, *51*, 5188–5197. (b) Bronstein, S. M.; Skopek, T. R.; Swenberg, J. A. Efficient Repair of O⁶-Ethylguanine, but not O⁴-Ethylthymine or O²-Ethylthymine, is dependent upon O⁶-Alkylguanine-DNA alkyltransferase and nucleotide excision repair activities in human cells. *Cancer Res.* **1982**, *52*, 2008–2011.

(41) Jaspers, N. G.; Raams, A.; Kelner, M. J.; Ng, J. M.; Yamashita, Y. M.; Takeda, S.; McMorris, T. C.; Hoeijmakers, J. H. Anti-Tumour Compounds Illudin S and Irofulven Induce DNA Lesions Ignored by Global Repair and Exclusively Processed by Transcription- and Replication-Coupled Repair Pathways. *DNA Repair* **2002**, *1*, 1027–1038.

(42) (a) Pearson, S. J.; Ferguson, J.; Santibanez-Koref, M.; Margison, G. P. Inhibition of O⁶-Methylguanine-DNA Methyltransferase by an Alkyltransferase-like Protein from *Escherichia coli*. *Nucleic Acids Res.* **2005**, *33*, 3837–3844. (b) Pearson, S. J.; Wharton, S.; Watson, A.; Begum, G.; Butt, A.; Glynn, N.; Williams, D. M.; Shibata, T.; Santibanez-Koref, M.; Margison, G. P. A novel DNA damage recognition protein in *Schizosaccharomyces pombe*. *Nucleic Acids Res.* **2006**, *34*, 2347–2354.

(43) (a) Tubbs, J. L.; Latypov, V.; Kanugula, S.; Butt, A.; Melikishvili, M.; Kraehenbuehl, R.; Fleck, O.; Marriott, A.; Watson, A. J.; Verbeek, B.; McGown, G.; Thorncroft, M.; Santibanez-Koref, M. F.; Millington, C.; Arvai, A. S.; Kroeger, M. D.; Peterson, L. A.; Williams, D. M.; Fried, M. G.; Margison, G. P.; Pegg, A. E.; Tainer, J. A. Flipping of alkylated DNA damage bridges base and nucleotide excision repair. *Nature* **2009**, *459*, 808–813. (b) Wilkinson, O. J.; Latypov, V.; Tubbs, J. L.; Millington, C. L.; Morita, R.; Blackburn, H.; Marriott, A.; McGown, G.; Thorncroft, M.; Watson, A. J.; Connolly, B. A.; Grasby, J. A.; Masui, R.; Hunter, C. A.; Tainer, J. A.; Margison, G. P.; Williams, D. M. Alkyltransferase-like protein (At1) distinguishes alkylated guanines for DNA repair using cation- π interactions. *Proc. Natl. Acad. Sci. U.S.A.* **2012**, *109*, 18755–18760.